Agomelatine in the Treatment of Major Depressive Disorder: Potential for Clinical Effectiveness

By Kennedy Sidney H.   Rizvi Sakina J.  

CNS Drugs, Vol. 24, Iss. 6, 2010-06 ,pp. : 479-499

Adis International

Access to resources Recommend Favorite

Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks

By  

Current Neuropharmacology, Vol. 12, Iss. 5, 2014-09 ,pp. : 387-398

Bentham Science Publishers

Access to resources Recommend Favorite

Agomelatine: a guide to its use in major depressive disorder

By  

Drugs & Therapy Perspectives, Vol. 26, Iss. 2, 2010-02 ,pp. : 6-9

Adis International

Access to resources Recommend Favorite

A randomised, double‐blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine†

By  

Human Psychopharmacology: Clinical And Experimental (Electronic), Vol. 30, Iss. 4, 2015-07 ,pp. : 327-327

John Wiley & Sons Inc

Access to resources Recommend Favorite

Relative short‐term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder

By  

Human Psychopharmacology: Clinical And Experimental (Electronic), Vol. 33, Iss. 1, 2018-01 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite